-+ 0.00%
-+ 0.00%
-+ 0.00%

Lunai Bioworks Launches New Oncology Collaboration With Clinical-Stage Partner To Analyze Data From Randomized Phase 2 Metastatic Colorectal Cancer Trial

Benzinga·02/09/2026 14:19:15
Listen to the news

AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategy

SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ:LNAI), an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a clinical-stage partner to analyze data from a randomized Phase 2 metastatic colorectal cancer trial.